460 reports of this reaction
3.0% of all ROMOSOZUMAB AQQG reports
#5 most reported adverse reaction
OFF LABEL USE is the #5 most commonly reported adverse reaction for ROMOSOZUMAB AQQG, manufactured by Amgen, Inc. There are 460 FDA adverse event reports linking ROMOSOZUMAB AQQG to OFF LABEL USE. This represents approximately 3.0% of all 15,195 adverse event reports for this drug.
Patients taking ROMOSOZUMAB AQQG who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for ROMOSOZUMAB AQQG, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for ROMOSOZUMAB AQQG:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 460 FDA reports for ROMOSOZUMAB AQQG. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 3.0% of all adverse event reports for ROMOSOZUMAB AQQG, making it a notable side effect.
If you experience off label use while taking ROMOSOZUMAB AQQG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.